Cancer-associated fibroblasts (CAFs) are an important component in solid tumors. They play a decisive role in cancer development and have a significant influence on the success of therapy.
ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ...